Stocktoria
Stoke Therapeutics, Inc. STOK
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-19
Stoke Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -11.2% | -277.3% | -1307.2% | -841.2% | — |
| Net margin | -3.7% | -243.4% | -1192.5% | -814.7% | — |
| FCF margin | 24.4% | -238.1% | -941.7% | -288.8% | — |
| Return on assets | -1.6% | -32.8% | -45.9% | -39.5% | -35.9% |
| Return on equity | -2.0% | -38.9% | -65.6% | -54.7% | -39.4% |
| Current ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 |
| Revenue growth | 404.5% | 316.3% | -29.2% | — | — |
Source: SEC EDGAR filings · CIK 0001623526 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.